ICRF-159 - CURRENT STATUS AND CLINICAL PROSPECTS

被引：31

作者：

BELLET, RE

ROZENCWEIG, M

VONHOFF, DD

PENTA, JS

WASSERMAN, TH

MUGGIA, FM

机构：

[1] INST CANC RES,PHILADELPHIA,PA 19111

[2] TEMPLE UNIV,SCH MED,PHILADELPHIA,PA 19111

[3] NCI,PROGRAM CANC THERAPY EVALUAT,BETHESDA,MD 20014

来源：

EUROPEAN JOURNAL OF CANCER | 1977年 / 13卷 / 11期

关键词：

D O I：

10.1016/0014-2964(77)90038-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1293 / 1298

页数：6

共 38 条

[1]

ATHERTON A, 1975, CANCER RES, V35, P953

[2] ICRF 159, (+/-) 1,2-DI(3,5-DIOXOPIPERAZIN-1-YL)PROPANE NSC-129,943 - RAZOXANE [J].

BAKOWSKI, MT .

CANCER TREATMENT REVIEWS, 1976, 3 (02) :95-107

[3]

BELLET RE, 1976, CANCER TREAT REP, V60, P1395

[4]

BELLET RE, 1973, CANCER CHEMOTH REP 1, V57, P185

[5] STUDY OF ANTITUMOR (PHASE-2) AND IMMUNOSUPPRESSIVE EFFECTS OF ICRF-159 IN PATIENTS WITH METASTATIC MELANOMA [J].

BELLET, RE ;

CATALANO, RB ;

DANNA, VG ;

BERD, DA ;

BERKELHAMMER, J ;

MASTRANGELO, MJ .

JOURNAL OF CLINICAL PHARMACOLOGY, 1976, 16 (8-9) :433-438

[6]

BELLET RE, 1975, P AM SOC CLIN ONCOL, V15, P224

[7]

BELLET RE, 1976, WADLEY MED B, V6, P76

[8] COMBINATION THERAPY WITH DRUGS AND RADIATION [J].

BLEEHEN, NM .

BRITISH MEDICAL BULLETIN, 1973, 29 (01) :54-58

[9] CANCER-TREATMENT TODAY AND ITS IMPACT ON DRUG DEVELOPMENT, WITH SPECIAL EMPHASIS ON PHASE-2 CLINICAL-TRIAL [J].

CARTER, SK .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1976, 57 (02) :235-244

[10] ANTI-METASTASIS EFFECT OF 2 DERIVATIVES OF EPIPODOPHYLLOTOXIN IN MICE [J].

CATTAN, A ;

POURNY, C ;

CARPENTIER, Y ;

CATTAN, E ;

BAROUH, M .

EUROPEAN JOURNAL OF CANCER, 1976, 12 (10) :797-805

← 1 2 3 4 →